Rivastigmine tartrate is primarily used in the treatment of mild to moderate dementia associated with Alzheimer's disease and Parkinson's disease. It works by inhibiting the breakdown of acetylcholine and butyrylcholine in the brain, thereby improving cognitive function, memory, and the ability to perform daily activities. The medication is available in oral and transdermal forms, with the patch offering a convenient option for patients who have difficulty swallowing or prefer a non-oral route. It is also beneficial in managing behavioral symptoms such as apathy, agitation, and hallucinations, which are common in dementia patients. Regular monitoring and dose adjustments are often required to balance efficacy and minimize side effects like nausea, vomiting, and dizziness. Overall, it plays a significant role in enhancing the quality of life for individuals with neurodegenerative conditions.